LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.94M | 11.63M | 10.57M | 9.02M | 7.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.94M | 11.63M | 10.57M | 9.02M | 7.43M |
| Cost of Revenue | 9.04M | 8.71M | 8.17M | 7.23M | 6.20M |
| Gross Profit | 3.90M | 2.92M | 2.39M | 1.79M | 1.22M |
| SG&A Expenses | 3.70M | 3.48M | 3.20M | 2.90M | 4.22M |
| Depreciation & Amortization | -47.20K | -48.50K | -49.60K | -49.60K | -49.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.69M | 12.14M | 11.32M | 10.15M | 10.47M |
| Operating Income | 246.40K | -507.70K | -758.70K | -1.14M | -3.04M |
| Income Before Tax | 2.38M | -1.80M | -2.09M | -2.48M | -6.27M |
| Income Tax Expenses | 35.70K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.35 | -1.80 | -2.09 | -2.48 | -6.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.35M | -1.80M | -2.09M | -2.48M | -6.27M |
| EBIT | 246.40K | -507.70K | -758.70K | -1.14M | -3.04M |
| EBITDA | 1.20M | 266.40K | 14.60K | -402.50K | -2.37M |
| EPS Basic | 0.02 | -0.02 | -0.02 | -0.03 | -0.08 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 |
| EPS Diluted | 0.02 | -0.02 | -0.03 | -0.03 | -0.09 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 421.36M | 387.86M | 355.21M | 331.87M | 317.32M |
| Average Diluted Shares Outstanding | 421.67M | 388.17M | 355.33M | 331.87M | 317.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |